Drug Profile

Research programme: small molecule cancer therapeutics - Sibylla Biotech

Latest Information Update: 17 Jun 2024

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Sibylla Biotech; University of Texas M. D. Anderson Cancer Center
Developer Sibylla Biotech
Class Antineoplastics; Small molecules
Mechanism of Action

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

12 Jun 2024 Sibylla Biotech and the University of Texas MD Anderson Cancer Center enter into a R&D agreement to discover and develop small-molecule cancer therapies
16 Jan 2024 Early research in Cancer in Italy (unspecified route) before January 2024 (Sibylla Biotech pipeline, January 2024)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com